Apollo Hospitals announces a collaboration with Precisio Biotix focused on next-generation lysin science to support India’s response to antimicrobial resistance (AMR). Both reports describe the partnership as part of efforts to develop and apply lysin-based approaches that target resistant pathogens, reflecting a broader move in healthcare toward alternatives to traditional antibiotics as AMR expands. The articles frame the cooperation around bringing newer lysin science into clinical and research work associated with AMR challenges in India. Apollo Hospitals is presented as the implementing healthcare organization, while Precisio Biotix is described as the partner providing the lysin technology or related scientific capability. The coverage is limited in detail, with both sources repeating the same core information: the existence of the collaboration, the intended focus on lysin science, and the AMR context. No additional outcomes, timelines, study results, or regulatory milestones are included in the provided summaries.